Marshall Wace, LLP Ikena Oncology, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding IKNA
# of Institutions
60Shares Held
30.4MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$7.68 Million1.07% of portfolio
-
Bvf Inc San Francisco, CA4.77MShares$7.3 Million0.26% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$6.26 Million2.33% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$5.42 Million0.14% of portfolio
-
Omega Fund Management, LLC Boston, MA2.25MShares$3.44 Million5.77% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $55.5M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...